Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-01-2014 | Original Article

Evaluation of the PET component of simultaneous [¹⁸F]choline PET/MRI in prostate cancer: comparison with [¹⁸F]choline PET/CT

Authors: Axel Wetter, Christine Lipponer, Felix Nensa, Philipp Heusch, Herbert Rübben, Jens-Christian Altenbernd, Thomas Schlosser, Andreas Bockisch, Thorsten Pöppel, Thomas Lauenstein, James Nagarajah

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2014

Abstract

Purpose

The aim of this study was to evaluate the positron emission tomography (PET) component of [¹⁸F]choline PET/MRI and compare it with the PET component of [¹⁸F]choline PET/CT in patients with histologically proven prostate cancer and suspected recurrent prostate cancer.

Methods

Thirty-six patients were examined with simultaneous [¹⁸F]choline PET/MRI following combined [¹⁸F]choline PET/CT. Fifty-eight PET-positive lesions in PET/CT and PET/MRI were evaluated by measuring the maximum and mean standardized uptake values (SUV_max and SUV_mean) using volume of interest (VOI) analysis. A scoring system was applied to determine the quality of the PET images of both PET/CT and PET/MRI. Agreement between PET/CT and PET/MRI regarding SUV_max and SUV_mean was tested using Pearson’s product-moment correlation and Bland-Altman analysis.

Results

All PET-positive lesions that were visible on PET/CT were also detectable on PET/MRI. The quality of the PET images was comparable in both groups. Median SUV_max and SUV_mean of all lesions were significantly lower in PET/MRI than in PET/CT (5.2 vs 6.1, p < 0.05 and 2.0 vs 2.6, p < 0.001, respectively). Pearson’s product-moment correlation indicated highly significant correlations between SUV_max of PET/CT and PET/MRI (R = 0.86, p < 0.001) as well as between SUV_mean of PET/CT and PET/MRI (R = 0.81, p < 0.001). Bland-Altman analysis revealed lower and upper limits of agreement of −2.77 to 3.64 between SUV_max of PET/CT vs PET/MRI and −1.12 to +2.23 between SUV_mean of PET/CT vs PET/MRI.

Conclusion

PET image quality of PET/MRI was comparable to that of PET/CT. A highly significant correlation between SUV_max and SUV_mean was found. Both SUV_max and SUV_mean were significantly lower in [¹⁸F]choline PET/MRI than in [¹⁸F]choline PET/CT. Differences of SUV_max and SUV_mean might be caused by different techniques of attenuation correction. Furthermore, differences in biodistribution and biokinetics of [¹⁸F]choline between the subsequent examinations and in the respective organ systems have to be taken into account.

Soyka JD, Muster MA, Schmid DT, Seifert B, Schick U, Maralbell R, et al. Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2012;39:936–43.PubMedCrossRef

Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010;254:925–33.PubMedCrossRef

Wehrl F, Judenhofer MS, Wiehr S, Pichler BJ. Pre-clinical PET/MR: technological advances and new perspectives in biomedical research. Eur J Nucl Med Mol Imaging 2009;36 Suppl 1:S56–68.PubMedCrossRef

Hofmann M, Pichler B, Schölkopf B, Beyer T. Towards quantitative PET/MRI: a review of MR-based attenuation correction techniques. Eur J Nucl Med Mol Imaging 2009;36 Suppl 1:S93–104.PubMedCrossRef

Martinez-Möller A, Souvatzoglou M, Delso G, Bundschuh RA, Chefd’hotel C, Ziegler SI, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med 2009;50:520–6.PubMedCrossRef

Drzezga A, Souvatzoglou M, Eiber M, Beer AJ, Fürst S, Martinez-Möller A, et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 2012;53:845–55.PubMedCrossRef

Heusch P, Buchbender C, Beiderwellen K, Nensa F, Hartung-Knemeyer V, Lauenstein TC, et al. Standardized uptake values for [18F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI. Eur J Radiol 2013;82:870–6.PubMedCrossRef

Bini J, Izquierdo-Garcia D, Mateo J, Machac J, Narula J, Fuster V, et al. Preclinical evaluation of MR attenuation correction versus CT attenuation correction on a sequential whole-body MR/PET scanner. Invest Radiol 2013;48:313–22.PubMedCrossRef

Kim JH, Lee JS, Song IC, Lee DS. Comparison of segmentation-based attenuation correction methods for PET/MRI: evaluation of bone and liver standardized uptake value with oncologic PET/CT data. J Nucl Med 2012;53:1878–82.PubMedCrossRef

10.

Wiesmüller M, Quick HH, Navalpakkam B, Lell MM, Uder M, Ritt P, et al. Comparison of lesion detection and quantitation of tracer uptake between PET from a simultaneously acquiring whole-body PET/MR hybrid scanner and PET from PET/CT. Eur J Nucl Med Mol Imaging 2013;40(1):12–21.PubMedCrossRef

11.

Akbarzadeh A, Ay MR, Ahmadian A, Alam NR, Zaidi H. MRI-guided attenuation correction in whole-body PET/MR: assessment of the effect of bone attenuation. Ann Nucl Med 2013;27:152–62.PubMedCrossRef

12.

Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004;45:1519–27.PubMed

13.

Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 2008;35:2320–33.PubMedCrossRef

14.

Antoch G, Freudenberg LS, Stattaus J, Jentzen W, Mueller SP, Debatin JF, et al. Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR Am J Roentgenol 2002;179:1555–60.PubMedCrossRef

15.

Oprea-Lager DE, Vincent AD, van Mooreslaar RJ, Gerritsen WR, van den Eertwegh AJ, Eriksson J, et al. Dual-phase PET-CT to differentiate [18F]fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer. PLoS One 2012;7:e48430.PubMedCrossRef

16.

Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T, et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006;33:1387–98.PubMedCrossRef

17.

Souvatzoglou M, Eiber M, Takei T, Fürst S, Maurer T, Gaertner F, et al. Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging 2013 [Epub ahead of print].

18.

Giussani A, Janzen T, Uusijärvi-Lizana H, Tavola F, Zankl M, Sydoff M, et al. A compartmental model for biokinetics and dosimetry of 18F-choline in prostate cancer patients. J Nucl Med 2012;53:985–93.PubMedCrossRef

19.

Kershah S, Partovi S, Traughber BJ, Muzic RF Jr, Schluchter MD, O’Donnell JK, et al. Comparison of standardized uptake values in normal structures between PET/CT and PET/MRI in an oncology patient population. Mol Imaging Biol 2013 [Epub ahead of print].

20.

Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1(8476):307–10.PubMedCrossRef

Title: Evaluation of the PET component of simultaneous [18F]choline PET/MRI in prostate cancer: comparison with [18F]choline PET/CT
Authors: Axel Wetter
Christine Lipponer
Felix Nensa
Philipp Heusch
Herbert Rübben
Jens-Christian Altenbernd
Thomas Schlosser
Andreas Bockisch
Thorsten Pöppel
Thomas Lauenstein
James Nagarajah
Publication date: 01-01-2014
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2560-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evaluation of the PET component of simultaneous [¹⁸F]choline PET/MRI in prostate cancer: comparison with [¹⁸F]choline PET/CT

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2014

First imaging results of an intraindividual comparison of 11C-acetate and 18F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy

Combined 99mTc-methoxyisobutylisonitrile scintigraphy and fine-needle aspiration cytology offers an accurate and potentially cost-effective investigative strategy for the assessment of solitary or dominant thyroid nodules

Treatment monitoring with 18F-FDG PET/CT in a patient with peritoneal tuberculosis

Prof. Ajit Padhy MBBS, MNAMS, FAMS

Sequential 18F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy

Heinrich Iro, Alessandro Bozzato and Johannes Zenk (Eds): Atlas of Head and Neck Ultrasound